Literature DB >> 18314347

Primary aldosteronism: cardiovascular, renal and metabolic implications.

Gian-Paolo Rossi1, Leonardo A Sechi, Gilberta Giacchetti, Vanessa Ronconi, Pasquale Strazzullo, John W Funder.   

Abstract

For many years primary aldosteronism was considered a relatively benign form of hypertension. This assumption reflects the primacy accorded to elevated levels of angiotensin in terms of deleterious cardiovascular effects, and the fact that in primary aldosteronism renin and angiotensin levels are low. We now know that primary aldosteronism causes a constellation of cardiovascular, renal and metabolic sequelae which make it far from benign and that these are not merely effects of blood pressure elevation. In primary aldosteronism, tissue damage, on several indices, is higher than in age-, sex- and blood pressure-matched controls, reflecting the ability of inappropriately elevated aldosterone for salt status to produce structural and functional changes over and above those produced by high blood pressure.

Entities:  

Mesh:

Year:  2008        PMID: 18314347     DOI: 10.1016/j.tem.2008.01.006

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  54 in total

Review 1.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

Review 2.  Aldosterone and cardiovascular risk.

Authors:  Bruno Vogt; Michel Burnier
Journal:  Curr Hypertens Rep       Date:  2009-12       Impact factor: 5.369

3.  Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment.

Authors:  Guido Zavatta; Guido Di Dalmazi; Carmine Pizzi; Giovanni Bracchetti; Cristina Mosconi; Caterina Balacchi; Uberto Pagotto; Valentina Vicennati
Journal:  Endocrine       Date:  2018-11-14       Impact factor: 3.633

4.  Refining the Definitions of Biochemical and Clinical Cure for Primary Aldosteronism Using the Primary Aldosteronism Surgical Outcome (PASO) Classification System.

Authors:  B S Miller; A F Turcu; A T Nanba; D T Hughes; M S Cohen; P G Gauger; R J Auchus
Journal:  World J Surg       Date:  2018-02       Impact factor: 3.352

Review 5.  The multifaceted mineralocorticoid receptor.

Authors:  Elise Gomez-Sanchez; Celso E Gomez-Sanchez
Journal:  Compr Physiol       Date:  2014-07       Impact factor: 9.090

6.  11-Deoxycortisol may be superior to cortisol in confirming a successful adrenal vein catheterization without cosyntropin: a pilot study.

Authors:  Naris Nilubol; Steven J Soldin; Dhaval Patel; Muthoni Rwenji; Jianghong Gu; Likhona S Masika; Richard Chang; Constantine A Stratakis; Electron Kebebew
Journal:  Int J Endocr Oncol       Date:  2017-04-27

7.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

8.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

9.  Increased aldosterone among HIV-infected women with visceral fat accumulation.

Authors:  Janet Lo; Sara E D Looby; Jeffrey Wei; Gail K Adler; Steven K Grinspoon
Journal:  AIDS       Date:  2009-11-13       Impact factor: 4.177

10.  Clinical management of primary aldosteronism: 2013 Practical Recommendations of the Italian Society of Hypertension (SIIA).

Authors:  Gian Paolo Rossi; Anna Dalla Cà
Journal:  High Blood Press Cardiovasc Prev       Date:  2014-01-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.